The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
BUSINESS
Daiichi Sankyo Bags FDA Nod for FLT3 Inhibitor in 1st Line AML
Daiichi Sankyo’s FLT3 inhibitor Vanflyta (quizartinib) gained US approval on July 20, four years after its initial Japanese blessing and rejection by the FDA. The drug is now approved for the first-line treatment of acute myeloid leukemia (AML) with FLT3-ITD…
To read the full story
Related Article
- Daiichi Sankyo’s FLT3 Inhibitor Gets EU Approval for 1st Line AML
November 10, 2023
- US FDA Extends Target Date for Daiichi Sankyo’s FLT3 Inhibitor by 3 Months
April 24, 2023
- Daiichi Sankyo’s FLT3 Inhibitor Gets FDA’s Priority Review for 1st Line AML
October 26, 2022
- Daiichi Sankyo Files Vanflyta for Frontline AML in Japan
August 31, 2022
- Daiichi Sankyo’s Quizartinib Accepted for European Review in 1st Line AML
August 24, 2022
- Quizartinib Cuts Risk of Death by 22.4% in 1st Line AML: Daiichi Sankyo
June 14, 2022
- European Panel Snubs Daiichi Sankyo’s Quizartinib
October 21, 2019
- Daiichi Sankyo’s AML Drug Vanflyta Now Available
October 11, 2019
- Days after Japan OK, FDA Spurns Daiichi Sankyo’s Quizartinib
June 25, 2019
BUSINESS
- Takeda on Course to Stable Growth as Late-Stage Assets Near Market
May 9, 2025
- Lilly Japan Scores Double-Digit Growth for 2nd Year as Mounjaro Delivers
May 9, 2025
- Ono’s Profits Slide Over 60% as Deciphera Buyout Costs Swell
May 9, 2025
- Kyowa Kirin Announces Another Buyout Package; Job Cut Target Not Set
May 8, 2025
- Pfizer Seeks Wider Label for PARP Inhibitor Talzenna in Japan
May 8, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…